pathology report

BRAF Mutations in Colorectal Cancer

A BRAF mutation is found in approximately 8 to 12% of colorectal cancers and identifies a biologically distinct subtype of the disease with its own treatment implications. The great majority of BRAF mutations in colorectal cancer are a specific change called V600E. This mutation carries two important clinical consequences: it predicts that standard anti-EGFR targeted …
Read More »

KRAS and NRAS Mutations in Colorectal Cancer

KRAS and NRAS are two of the most commonly tested genes in colorectal cancer. When either gene carries a mutation — a change that causes it to malfunction — the result has direct consequences for your treatment plan. Most importantly, KRAS and NRAS mutations predict that a class of targeted drugs called anti-EGFR therapy will …
Read More »

MMR-deficient (dMMR): Definition

MMR-deficient, often written as dMMR, means that one or more of the proteins responsible for repairing mistakes in a cell’s DNA are missing or not working properly. When these repair proteins are lost, errors in DNA can accumulate over time, contributing to the development of cancer. Finding dMMR in a tumour has important implications for …
Read More »

Mismatch Repair (MMR) and Microsatellite Instability (MSI) in Colorectal Cancer

Mismatch repair (MMR) and microsatellite instability (MSI) testing are among the most important biomarker tests performed on colorectal cancers. Every colorectal cancer — whether found on a biopsy or in a surgical specimen — should be tested for this biomarker. The results tell your doctor whether your cancer’s DNA repair system is working normally or …
Read More »

PD-L1 Testing in Cancer

PD-L1 (programmed death-ligand 1) is a protein found on the surface of cells, including cancer cells and immune cells within tumors, that acts as a brake on the immune system. Under normal circumstances, PD-L1 helps prevent the immune system from attacking healthy tissue by binding to a receptor called PD-1 on T cells, sending a …
Read More »

NTRK Fusions in Cancer

NTRK fusions are chromosomal rearrangements that fuse one of three genes — NTRK1, NTRK2, or NTRK3 — to a partner gene, producing an abnormal fusion protein that continuously drives cancer cell growth. The NTRK genes normally encode a family of receptor proteins called tropomyosin receptor kinases (TRK A, B, and C), which play important roles …
Read More »

BRAF Mutations in Lung Cancer

BRAF is a gene that encodes a protein kinase — an enzyme that acts as a relay in a signalling chain called the MAPK pathway, which controls cell growth and division. In normal cells, BRAF passes signals from activated surface receptors (including RAS proteins) downstream to the rest of the cell in a tightly regulated …
Read More »

RET Fusions in Lung Cancer

RET is a gene that encodes a receptor protein involved in signalling pathways that regulate cell growth, survival, and differentiation during normal development. In healthy adult lung tissue, RET activity is minimal. In approximately 1–2% of non-small cell lung cancers, a chromosomal rearrangement fuses the RET gene to a partner gene, creating an abnormal fusion …
Read More »

MET alterations in Lung Cancer

MET (also called c-MET or HGFR — hepatocyte growth factor receptor) is a protein found on the surface of cells that receives signals from a molecule called hepatocyte growth factor (HGF). When HGF binds to MET, it activates signalling pathways that promote cell growth, survival, and movement — processes that are tightly regulated in normal …
Read More »

ROS1 Rearrangements in Lung Cancer

ROS1 is a gene that encodes a receptor protein involved in signalling pathways that regulate cell growth and survival. In healthy adult lung tissue, ROS1 is essentially inactive. In approximately 1–2% of non-small cell lung cancers, a chromosomal rearrangement fuses the ROS1 gene to a partner gene, creating an abnormal fusion protein that is permanently …
Read More »

1 5 6 7 8 9 115
A+ A A-